Abstract
Background As coronavirus 2019 (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. Hence, we performed a retrospective cohort study to identify predictors of both infections.
Methodology/Principal Findings All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed. Over a two-month study period, we diagnosed 80 COVID-19, 60 non-severe dengue and 872 OFIs cases. Among these, we identified delayed presentation (>3 days) since symptom onset (Odds ratio 1.91, 95% confidence interval 1.07-3.39), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.21-6.55) and anosmia (OR 7.80, 95%CI 4.20-14.49) as independent predictors of COVID-19, body ache (OR 6.17, 95%CI 2.69-14.14), headache (OR 5.03, 95%CI 1.88-13.44) and retro-orbital pain (OR 5.55, 95%CI 2.51-12.28) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.09-0.79) and upper respiratory tract infection symptoms were associated with OFIs.
Conclusions/Significance Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates. At clinical presentation, eight basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.
Author Summary As coronavirus 2019 (COVID-19) is spreading globally, several countries are facing dengue epidemics with the fear the two plagues might overburden their healthcare systems. On Reunion island, southwestern Indian ocean: dengue virus is circulating since 2004 under an endemo-epidemic pattern with yearly outbreaks peaking between March and May since 2015, whereas Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the pathogen responsible of COVID-19, emerged in March 2020, imported from the Bahamas. COVID-19 and dengue are deemed two clinically similar entities, especially within the first two days from symptom onset. In this context, we conducted a cohort study between March 23 and May 10, 2020, within a SARS-CoV-2 testing center, aimed at identifying the factors discriminating both infections. Surprisingly, we found that non-severe dengue was more symptomatic than mild to moderate COVID-19. Indeed, we found body ache, headache and retro-orbital pain to be indicative of dengue, whereas contact with a COVID-19 positive case, anosmia, delayed presentation (>3 days post symptom onset) and absence of active smoking were indicative of COVID-19. These findings highlight the need for accurate diagnostic tools and not to jeopardize dengue control in areas wherever COVID-19 dengue co-epidemics have the potential to wrought havoc to the healthcare system.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding for this study conducted within standard care procedures
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Outpatients presenting consecutively at the SARS-CoV-2 testing center were informed of the study orally and by means of an information sheet. Adult people, like the children under 18 years (with the additional verbal consent of their parent or legal guardian) who expressed no opposition, were asked to answer a questionnaire and surveyed in face-to-face by a nurse, in accordance to the French legislation on bioethics for retrospective researches. Patient medical records were retrospectively reviewed, and de-identified data were collected in standardized forms according to the MR-004 procedure of the Commission Nationale Informatique et Libertes (the French information protection commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of the CHU Reunion and de-identified data were registered on the Health Data Hub.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵†‡ Contributed equally
Background. As coronavirus 2019 (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. Hence, we performed a retrospective cohort study to identify predictors of both infections. Methodology/Principal Findings. All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed. Over a two-month study period, we diagnosed 80 COVID-19, 60 non-severe dengue and 872 OFIs cases. Among these, we identified delayed presentation (>3 days) since symptom onset (Odds ratio 1.91, 95% confidence interval 1.07-3.39), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.21-6.55) and anosmia (OR 7.80, 95%CI 4.20-14.49) as independent predictors of COVID-19, body ache (OR 6.17, 95%CI 2.69-14.14), headache (OR 5.03, 95%CI 1.88-13.44) and retro-orbital pain (OR 5.55, 95%CI 2.51-12.28) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.09-0.79) and upper respiratory tract infection symptoms were associated with OFIs. Conclusions/Significance. Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates. At clinical presentation, eight basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.
Data Availability
The data will be processed for the development of a scoring system. After having submitted our second paper, we will provide an access to the data in a data repository according to data sharing. In the meantime, data availability will be discussed on request
List of abbreviations
- CIR
- cumulative incidence rate (= attack rate)
- CNR
- centre national de reference
- COVID-19
- coronavirus disease of 2019
- DENV
- dengue virus
- OFIs
- other febrile illnesses
- aOR
- adjusted odds ratio
- RT-PCR
- reverse transcription – polymerase chain reaction
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- SpO2
- Saturation of peripheral oxygen
- UDACS
- unite de dépistage ambulatoire du coronavirus sud
- URTI
- upper respiratory tract infection
- 95% CI
- 95% confidence intervals
